JP2016504381A5

JP2016504381A5 -

Info

Publication number: JP2016504381A5
Application number: JP2015551671A
Authority: JP
Filing date: 2013-10-25
Publication date: 2016-12-08
Anticipated expiration: 2033-10-25

Claims

Therapy of or worsening a disease caused by a microorganism, or therapy of symptoms of the disease, or used in combination of both, a barrier-forming composition comprising an antimicrobial agent,
The treatment is carried out by administering to the surface of the barrier-forming composition of therapeutically effective amounts, to treat the disease, to treat the symptoms of the disease, or to shorten the duration of disease, or both thereof And
( Wherein the surface comprises a mucosal membrane of a mammal, the mammal suffers from or develops symptoms of the disease caused or exacerbated by the microorganism ) ;
And forming a barrier coating is effective to kill or neutralize the microorganisms in contact with the barrier coating on said surface, a barrier-forming composition.

The treatment effectively reduces the load of the microorganism on the surface , or reduces the duration, frequency, or severity of one or more of cough, sore throat, and fever. The barrier-forming composition according to claim 1, further comprising:

Said treatment, wherein the disease, or one or more periods of symptoms of the disease, frequently Tabimata further seen contains reducing the severity, one or more symptoms of the disease, runny nose, nausea, cough, headache, sneezing, tightness of the paranasal sinuses, aches and pain, watery eyes, sore throat, stuffy nose, chills, vomiting, fatigue, at least 1 Tsuo含 free of fatigue, rhinorrhea, and fever, The barrier-forming composition according to claim 1.

The disease is selected from the group consisting of influenza, rhinovirus, bacterial upper or lower respiratory tract infection, viral upper or lower respiratory tract infection, streptococcal infection, staphylococcal infection, and ventilator-associated pneumonia The barrier-forming composition according to claim 1, wherein the barrier-forming composition is one or more diseases or upper respiratory tract infections .

2. The barrier-forming composition of claim 1, wherein multiple symptoms of upper respiratory tract infection are treated by administering the barrier-forming composition .

The treatment comprises administering a therapeutically effective amount of the barrier-forming composition to the surface over one, two or more, at least two consecutive periods of 24 hours , or a therapeutically effective amount of the barrier-forming composition; 2. The barrier-forming composition of claim 1 , further comprising administering to the surface 3 or more times within 24 hours, over a period of at least 2 consecutive 24 hours .

Wherein from 1 to 6 hours after administration step, or load of the microorganism decreases 2 5% to 9 9%, or,
The mucosa is one or more of oral mucosa, nasal mucosa and pharyngeal mucosa, or
The barrier layer has a bactericidal or bacteriostatic effect over a duration of 6 to 24 hours, or
The barrier-forming composition is either applied by spraying, or is a solution, a barrier-forming composition of claim 1.

The barrier-forming composition according to claim 1, wherein the antibacterial agent is a broad spectrum antibacterial agent or a monoquaternary ammonium compound .

The microorganism is Candida, Pneumonia, methicillin-resistant Staphylococcus aureus, Streptococcus, Porphyromonas gingivalis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans, Staphylococcus aureus, Yersinia enterocolitica, Acinetobacter baumannii, Sanguinea Streptococcus, Streptococcus Oralis, Streptococcus mitis, Streptococcus salvarius, Streptococcus gordonii, Aggregatebacter actinomycetemcomitans, Fusobacterium nucleatum, Candida albicans, Candida crusica・ Grabrata, microorganisms that cause upper respiratory tract infections, microorganisms that cause lower respiratory tract infections, HIV, rhinovirus, EBV, and Or is selected from the group consisting of influenza virus, or Candida, pneumoniae, methicillin-resistant Staphylococcus aureus, streptococci, P. gingivalis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans, Staphylococcus aureus, Yersinia・ Enterocolitica, Acinetobacter baumannii, Sanguinea streptococci, Streptococcus oralis, Streptococcus mitis, Streptococcus salivaius, Streptococcus gordonii, Aggregatebacter actinomycetemcomitans, Fusobacterium candigenum・ Cruise, Candida tropicalis, Candida glabrata, HIV, EBV, influenza virus, upper respiratory tract infection Microorganisms causing respiratory tract infections, microorganisms causing lower respiratory tract infections, Sentipeda periodonti, Eickenella collodence, enterobacteria, Fusobacterium nucleatum subspecies nucleatum, Fusobacterium nucleatum subsp. Cam, Porphyromonas Endontalis, Prevotella (Bacteroides) Melanino Genica, Prevotella Intel Media, Bacteroides (Bacteroides) Lachae, Solobacterium Murray, Tannerrella Forsysia (Bacteroides Forsycia), Treponema Denticola, Clostridium Difficile, Bordetella pertussis, Burkholderia, Aspergillus fumigatsu , Penicillium genus, Cladosporium, HPV, Common cold virus, Klebsiella pneumoniae, Hog cholerae, Escherichia coli (O157: H7), Trichodermatosis, rhinovirus, RS virus, poliovirus type 1, rotavirus Wa strain, A The barrier-forming composition according to claim 1, selected from the group consisting of influenza virus, herpes simplex virus types 1 and 2, and hepatitis A virus .

The barrier coating has the effect of capturing and killing or neutralizing microorganisms in contact with the barrier coating for a duration of at least 1 hour, or
The barrier-forming composition includes a wetting agent, an antimicrobial agent, and optionally a gum, where the gum is present in an amount of 0.01% to 0.4% by weight of the total barrier-forming composition. to the barrier-forming composition of claim 1.

The barrier-forming composition satisfies the following requirements, the barrier-forming composition according to claim 1:
0 .0001% ≦ C ≦ 0 .4 %;
0 .07% ≦ H ≦ 7 0 %; and
0.0005% <A
Or
0 % ≦ C ≦ 0.4 %;
5 5% ≤ H ≤ 70 %; and
0.0005% <A,
Where all percentages are by weight of the total composition;
C is a carbohydrate gum; H is a wetting agent; and A is an antibacterial agent.

Wherein the step of administering the barrier-forming composition is performed in accordance with the following, the barrier-forming composition according to claim 1:
a. By (here to identify a contaminated environment to be that the mammal is or there exists, the contaminated environment is harmful viruses are known that you have been contaminated with fungi, or bacteria, or expected It is Ru); or b. A contamination event is observed in the environment (where the mammal is or will be present in the environment at a high risk state).

The barrier-forming composition has a viscosity of less than 500 cps, has a bactericidal or bacteriostatic action for a duration of 6-24 hours, or kills microorganisms or anti-adhesion via nanoemulsion activity 2. The barrier-forming composition according to claim 1, wherein the barrier-forming composition is not effective in functioning by keeping microorganisms away from the mechanism .

A composition comprising an aqueous solution and satisfying the following requirements:
0 .0001% ≦ C ≦ 0 .4 %;
0 .07% ≦ H ≦ 7 0 %; and
0.0005% <A
Or
0 % ≦ C ≦ 0.4 %;
5 5% ≤ H ≤ 70 %; and
0.0005% <A,
(Where all percentages are by weight of the total composition;
C is a carbohydrate gum; H is a wetting agent; and A is an antimicrobial agent); and
Contains a second active substance that acts to reduce symptoms of infectious diseases ,
(I) the composition satisfies 5% ≦ H ≦ 45%; and 0.05% <A ≦ 5%, or
(Ii) the second active substance is calcium carbonate and magnesium, magnesium hydroxide and aluminum, sodium carbonate, sodium bicarbonate, and C ₇ H ₅ BiO ₄ , resveratrol, flavonoid, anthocyanin, psyllium seed husk, sulforaphane, Kusotatsu, isoflavonoid, alpha linolenic acid, omega-3 fatty acid, ginseng, garlic oil, thiol, carotene, ubiquinol, ascorbic acid, polyphenol, nonspecific immune stimulant, endogenous immune stimulant, deoxycholic acid, macrophage stimulant , Synthetic immunostimulant, macrokine, imiquimod, resiquimod, granulocyte-macrophage colony stimulating factor, bismuth disalicylate, methylcellulose, plant fiber, guar gum, bran, stellclear, isagol, methylcellulo Absorbents, opioids, loperamide hydrochloride, olanzapine, 5-HT3 receptor antagonist, dopamine antagonist, dolasetron, NK1 receptor antagonist, aprepitant, histamine H1 receptor antagonist, cyclidine, diphenhydramine, cannabinoid, cannabis, dronabinol, benzodiazepine , Midazolam, lorazepam, anticholinergic drugs, hyoscine, steroids, dexamethasone, propionic acid derivatives, naproxen, ibuprofen, acetic acid derivatives, indomethacin, etodolac, enolic acid derivatives, fenamic acid derivatives, _COX- 2 derivatives, acetaminophen, sulfonanilide , Diclofenac, capsaicin, NSAIDs, ibuprofen, trolamine salicylic acid or methyl salicylate, mensacin, zostrikes, Soid ephedrine, phenylephrine, ephedrine, levomethamphetamine, naphazoline, oxymetazoline, phenylpropanolamine, propylhexedrine, synephrine, tetrahydrozoline, antitussives, dextromethorphan, codeine, noscapine, bromhexine, acetylcysteine, expectorant, mucus dissolution It is selected from one or more of drugs, honey, acetylcysteine, ambroxol, guinefecin, and other drugs that act to treat upper respiratory tract infections or symptoms of upper respiratory tract infections .

Treatment or worsening a disease caused by a microorganism, or treatment of the symptoms of the disease, or used in combination of both, a barrier-forming composition,
The barrier-forming composition comprises an antimicrobial agent that acts to cause cell death by binding to and disrupting the cell membrane of the microorganism;
The treatment, by administering the barrier-forming composition of therapeutically effective amount of a surface, to treat the disease, to treat the symptoms of the disease, or this and (where performing combination of both, The surface comprises mammalian mucosa, the mammal suffers from the disease caused or exacerbated by the microorganism );
Duration of the disease, frequency, or reducing the severity effectively, or one or more periods of symptoms of the disease, frequency, or severity and that effectively reduce the;
The barrier-forming composition, and a lack of adverse side effects to a safe, barrier-forming composition.